In recent guidelines and expert consensus documents of antithrombotic therapy for patients with ischemic heart disease, dual antithrombotic therapy with a P2Y12 inhibitor plus OAC is commonly recommended in atrial fibrillation (AF) patients after PCI [2–7]. Here, P2RY12 is linked to coronary artery disorder.